Societal costs of multiple sclerosis in Ireland

References

• Cottrell D, Kremenchutzky M, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. Brain 1999;122:625-39
   PubMed Web of Science ®Google Scholar
• McDonald I, Compston A. The symptoms and signs of multiple sclerosis. McAlpine’s Multiple Sclerosis 2006;4:321-2
   Google Scholar
• Trisolini M, Honeycutt A, Wiener J, et al. Global economic impact of multiple sclerosis. London, UK: Multiple Sclerosis International Federation; 2010
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurge Psychiatry 2006;77:918-26
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012;18(2Suppl):7-15
   Web of Science ®Google Scholar
• Taylor B, McDonald E, Fantino B, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci 2007;14:532-9
   PubMed Web of Science ®Google Scholar
• Ford HL, Gerry E, Johnson MH, Tennant A. Health status and quality of life of people with multiple sclerosis. Disabil Rehab 2001;23:516-21
   PubMed Web of Science ®Google Scholar
• Arnett P, Randolph J. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77:606-10
   PubMed Web of Science ®Google Scholar
• Horwath E, Johnson J, Klerman GL, et al. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 1992;49:817-23
   PubMed Web of Science ®Google Scholar
• Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387-94
   PubMed Web of Science ®Google Scholar
• Allison RS, Millar JHD. Prevalence of disseminated sclerosis. Ulster Med J 1954;23(Suppl2):5
   Google Scholar
• Brady R, Dean G, Secerbegovic S, et al. Multiple sclerosis in the Republic of Ireland. Irish Med J 1977;70:500
   PubMedGoogle Scholar
• Lonergan R, Kinsella K, Fitzpatrick P, et al. Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 2011;82:317-22
   PubMed Web of Science ®Google Scholar
• McGuigan C, McCarthy A, Quigley C, et al. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry 2004;75:572-6
   PubMed Web of Science ®Google Scholar
• Balk L, Tewarie P, Killestein J, et al. Disease course heterogeneity and OCT in multiple sclerosis. Mult Scler 2014;20:1198-206
   PubMedGoogle Scholar
• Patwardhan M, Matchar D, Samsa G, et al. Cost of multiple sclerosis by level of disability: a review of literature. Multiple Sclerosis 2005;11:232-9
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11-25
   PubMedGoogle Scholar
• Fogarty E, Walsh C, McGuigan C, et al Direct and indirect economic consequences of multiple sclerosis in Ireland. Appl Health Econ Health Policy 2014;12:635-45
   PubMedGoogle Scholar
• Kelly S, Fogarty E, Duggan M, et al. Economic costs associated with an MS relapse. Multiple Sclerosis Relat Disord 2014;3:678-83
   PubMed Web of Science ®Google Scholar
• McCrone P. Capturing the costs of end-of-life care: comparisons of multiple sclerosis, Parkinson’s disease, and dementia. J Pain Symptom Manag 2009;38:62-7
   PubMed Web of Science ®Google Scholar
• van Hout B, Janssen M, Feng Y-S, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15
   Web of Science ®Google Scholar
• Oppe M, Devlin NJ, Szende A. EQ-5D value sets: inventory, comparative review and user guide. Netherlands: Springer; 2007
   Google Scholar
• Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-91
   PubMed Web of Science ®Google Scholar
• Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22:117-39
   PubMed Web of Science ®Google Scholar
• Gray O, McDonnell G, Hawkins S. Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. Multiple Sclerosis 2008;14:880-6
   PubMedGoogle Scholar
• CSO. Consumer Price Index. 2011. Available at: http://www.cso.ie/en/releasesandpublications/er/cpi/
   Google Scholar
• Smith S, Horgan F, Sexton E, et al. The cost of stroke and transient ischaemic attack in Ireland: a prevalence-based estimate. Age Ageing 2012:41:332-8
   Google Scholar
• Zhang W, Anis A. Health-related productivity loss: NICE to recognize soon, good to discuss now. PharmacoEconom 2014;32:425-7
   PubMed Web of Science ®Google Scholar
• Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross‐sectional study in Sweden. Eur J Neurol 2001;8:27-35
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ HEPAC Health Econ Prevent Care 2006;7(Suppl2):S96-104
   Google Scholar
• Casado V, Romero L, Gubieras L, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Multiple Sclerosis 2007;13:800-4
   PubMed Web of Science ®Google Scholar
• Wundes A, Brown T, Bienen EJ, et al. Contribution of intangible costs to the economic burden of multiple sclerosis. J Med Econ 2010;13:626-32
   PubMedGoogle Scholar
• Gannon B, O’Shea E, Hudson E. Economic consequences of falls and fractures among older people. Ir Med J 2008;101:170-3
   PubMedGoogle Scholar
• Borgström F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporosis Int 2006;17:637-50
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York, UK: Centre for Health Economics, University of York; 1999
   Google Scholar
• HIQA. Guidelines for the economic evaluation of health technologies in Ireland. Dublin, Ireland: Health Information and Quality Authority; 2014
   Google Scholar
• Hawton A, Green C. Multiple sclerosis: relapses, resource use, and costs. Eur J Health Econ 2016;17:875-84
   PubMed Web of Science ®Google Scholar
• Doherty DT, Moran R, Kartalova-O’Doherty Y, et al. HRB national psychological wellbeing and distress survey: baseline results. Dublin, Ireland: Health Research Board; 2007
   Google Scholar
• Koch M, Uyttenboogaart M, van Harten A, et al. Fatigue, depression and progression in multiple sclerosis. Multiple Sclerosis 2008;14:815-22
   PubMedGoogle Scholar
• Kearney PM, Cronin H, O’Regan C, et al. Cohort profile: the Irish longitudinal study on ageing. Int J Epidemiol 2011;40:877-84
   PubMed Web of Science ®Google Scholar
• McDonnell G, Hawkins S. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998;50:423-8
   PubMed Web of Science ®Google Scholar
• Ruutiainen J, Viita A-M, Hahl J, et al. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality of life of Finnish patients with multiple sclerosis. J Med Econ 2016;19:21-33
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany. Multiple Sclerosis J 2012;18(2suppl):23-7
   Web of Science ®Google Scholar
• CSO. Labour market. Dublin, Ireland. 2016. Available at: http://www.cso.ie/en/statistics/labourmarket/
   Google Scholar
• O’Shea E, Kennelly B. The economics of mental health care in Ireland. Dublin, Ireland: Mental Health Commission; 2008. Available at: http://www.mhcirl.ie/File/ecommhceire.pdf
   Google Scholar
• Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev 2006;63:217-35
   PubMed Web of Science ®Google Scholar
• O’Connell K, Kelly SB, Fogarty E, Duggan M, Buckley L, Hutchinson M, McGuigan C, Tubridy N. Economic costs associated with an MS relapse. Mult Scler Relat Disord 2014;3:678-83
   PubMed Web of Science ®Google Scholar
• Snell T, Knapp M, Healey A, et al. Economic impact of childhood psychiatric disorder on public sector services in Britain: estimates from national survey data. J Child Psychol Psychiatry 2013;54:977-85
   PubMed Web of Science ®Google Scholar
• Beecham J, Knapp M. Costing psychiatric interventions, in Thornicroft G, Brewin C, Wing J (eds). Measuring Mental Health Needs. Oxford: Oxford University Press; 1992
   Google Scholar
• Tilson L, Sharp L, Usher C, et al. Cost of care for colorectal cancer in Ireland: a health care payer perspective. Eur J Health Econ 2012;13:511-24
   PubMed Web of Science ®Google Scholar
• Bourke S, Burns RM, Gaynor C. Challenges in generating costs and utilisation rates associated with castration-resistant prostate cancer. J Market Access Health Policy 2014:1-6
   Google Scholar